Univariate survival analysis of all 176 breast cancer patients composing the test set using the 65th percentile as cut-off revealed that breast cancer patients with high NFE2L2 mRNA expression levels had a better RFS (P = 0.013) in comparison to those with low NFE2L2 mRNA expression levels. This evidence concerns the gene NFE2L2 and breast carcinoma.